Myogen Pulmonary Blood Pressure Treatment Gets Fast Tracked
Posted on: Friday, 10 March 2006, 12:00 CST
The FDA has granted fast track designation to ambrisentan, a type-A selective endothelin receptor antagonist produced by Myogen, which is currently under development for pulmonary arterial hypertension.
Fast track programs are designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Such a designation means the FDA will review a potential new drug in approximately six months rather than taking the usual 10 or 12 months to complete the process.
Pulmonary arterial hypertension (PAH) is a life-threatening, progressive, and incurable disease of the pulmonary vasculature. It results in dangerously high blood pressure in the arteries near the lungs. Myogen is currently investigating the effects of ambrisentan for this indication in phase III clinical studies. Previous research suggests the drug may delay the clinical worsening of PAH.
"Based on clinical trial results to date and the properties of ambrisentan, Myogen believes that, if ambrisentan is ultimately approved, it may offer significant clinical benefit to PAH patients," said Dr Michael Gerber, senior vice president of clinical development and regulatory affairs for Myogen.
Ambrisentan is a non-sulfonamide, propanoic acid-class, type-A selective endothelin receptor antagonist. Endothelin is a small peptide hormone that plays a critical role in the control of blood flow and cell growth. Myogen believes that agents that block the detrimental effects of endothelin may provide significant benefits in the treatment of these conditions.
Myogen has licensed ambrisentan ex-US rights to GlaxoSmithKline. The drug has been granted orphan drug designation for the treatment of PAH in both the US and in European.
Source: Datamonitor
Related Articles
- Michael J. Fox Foundation Awards $3.8 Million To Drive Nine Industry Partnerships For Pre-Clinical Parkinson's Drug Development
- Thomson Reuters White Paper Explores the Role of Biomarkers in Clinical Trials and Drug Development
- Technology Pioneer 2009 - AC Immune Highlights Significant Clinical Milestones in Alzheimer's Disease Drug Development
- Novartis Institute for Tropical Diseases and Global Alliance for TB Drug Development Announce Five-Year Collaboration Targeted to Accelerate TB Treatment R&D
- New Book Acquaints Students and Practitioners in the Intricacies of New Drug Development
- OREXIGEN(TM) Therapeutics to Present CONTRAVE(TM) Clinical Summary at CBI's 3rd Annual Obesity Drug Development Summit
- Singulex Raises $19.1 Million to Advance Clinical Immunoassays for Drug Development and Health Care
- Idera Pharmaceuticals Announces Formation of Oncology Clinical Advisory Board; Accomplished Physicians and Scientists in Cancer Drug Development
- The NCI-Funded Standardized Expression Measurement (SEM) Center(TM) Based on StaRT-PCR(TM) Enables Multi-Institutional Clinical Trials and Facilitates Development of Drugs and Molecular Diagnostic Tests
- Research and Markets: Molecular Biomarkers for Clinical Diagnostics and Drug Discovery and Development
 |
 |
User Comments (0)
RSS Feeds